FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/Highlighting the potential of CG1/A2-targeting CAR T cells as a novel immunotherapy approach in myeloid malignancies.
返回研究图书馆
cathepsin G signal peptideCG1

Highlighting the potential of CG1/A2-targeting CAR T cells as a novel immunotherapy approach in myeloid malignancies.

May 16, 2026
Share

原始论文

T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.

Yan Jun et al.Leukemia2025
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文将上述源论文的研究成果分解成肽类研究社区易于理解的语言。我们的目标是突出最值得关注的内容 — 实用意义、证据强度以及对正在进行的研究的影响。

Novel CAR T Cells Targeting Cathepsin G Signal Peptide Show Promise in Leukemia Treatment

Published: May 16, 2026 | Source: Leukemia (2025) | Category: cathepsin G signal peptide, CG1

Overview

A recent study published in Leukemia reveals the potential of chimeric antigen receptor (CAR) T cells targeting a specific signal peptide derived from cathepsin G (CG), known as CG1. This research offers new hope for treating acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) by leveraging an innovative immunotherapy approach.

Study Background

Immunotherapies have revolutionized cancer treatment, but the development of effective targets in myeloid malignancies has been challenging. The study builds on previous research where a T cell receptor mimic antibody targeting CG1 was developed and shown to be safe and efficacious against AML and CML. This new work aims to extend these findings by engineering CAR T cells that can recognize and target the same HLA-A2-restricted signal peptide, CG1.

What the Research Found

Researchers engineered CAR T cells using a T cell receptor mimic (TCR-m) specific for CG1/A2 complexes. These modified CAR T cells demonstrated high affinity for both CG1/A2 monomers and leukemia cells expressing this complex. The study showed that these CAR T cells were effective in preclinical models of AML and CML, indicating their potential as a therapeutic tool against these diseases.

What This Means for Peptide Users

While the findings are promising, it is important to note that this research has only been conducted in preclinical settings. For peptide users, particularly those involved in immunotherapy development or clinical trials, the study highlights a new direction in targeting myeloid malignancies through specific signal peptides. However, further validation and clinical testing are necessary before these CAR T cells can be used in patient care.

Limitations and Caveats

The primary limitation of this research is its preclinical nature; no human subjects have been involved yet. Additionally, the study focuses on HLA-A2-restricted CG1/A2 complexes, which limits applicability to patients with this specific genetic marker. The safety and efficacy profiles in humans remain unknown until clinical trials are conducted.

How This Compares to Previous Research

This work builds upon earlier studies that established the feasibility of targeting CG1 using TCR-m antibodies. Unlike those previous efforts, however, this study introduces a novel approach by utilizing CAR T cells engineered with the same specificity. While both methods show promise in preclinical settings, the use of CAR T cells may offer advantages such as enhanced persistence and anti-tumor activity.

Our Analysis

PeptideVault views this research positively but emphasizes the need for caution due to its preliminary stage. The innovative approach of targeting a signal peptide with CAR T cells represents an exciting development in cancer immunotherapy, particularly for myeloid malignancies where effective targets have been scarce. However, rigorous clinical validation is essential before these findings can be translated into practical medical applications.

Key Takeaways

  • Novel Target: CG1/A2 complexes represent a promising new target for CAR T cell therapy.
  • Preclinical Success: The study demonstrates efficacy in preclinical models of AML and CML.
  • Clinical Validation Needed: Further research is required to confirm safety and effectiveness in human patients.

Original Source

Citation: Yan Jun, Shi Chunhua, Yang Guojun et al. (2025). T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.. Leukemia. DOI: 10.1038/s41375-025-02652-0

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

编辑注释

此分析由Peptide Contacts研究团队准备。鼓励读者查阅 完整源论文 以获取完整方法和数据。 原始出版物可在 PubMed.

Comments

Sign in to join the discussion

此分析基于同行评审研究仅用于教育目的。并不构成医疗建议。在使用任何肽类疗法之前,请咨询合格的医疗服务提供者。